<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977301</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 08.04</org_study_id>
    <nct_id>NCT00977301</nct_id>
  </id_info>
  <brief_title>Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)</brief_title>
  <acronym>FORZA</acronym>
  <official_title>The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of fosamprenavir/ritonavir (steady state) on the pharmacokinetics of a single dose&#xD;
      of olanzapine will be studied.&#xD;
&#xD;
      In this study, the investigators expect an inducible effect of fosamprenavir/ritonavir on the&#xD;
      CYP1A2 and UGT metabolism of olanzapine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychosis and other mental illnesses are commonly described in patients infected with the&#xD;
      human immunodeficiency virus (HIV). New-onset psychosis is estimated to occur in up to 15% of&#xD;
      patients infected with HIV while 5 to 7% of patients with HIV-infection suffer from&#xD;
      pre-existing mental illnesses including schizophrenia. Olanzapine could be an attractive&#xD;
      antipsychotic in HIV/AIDS patients with schizophrenia.&#xD;
&#xD;
      Because olanzapine is a substrate for both UGT and CYP1A2, the pharmacokinetics of olanzapine&#xD;
      might be influenced by low-dose ritonavir in combination with fosamprenavir. The current&#xD;
      study is designed to test this hypothesis. Furthermore, in this study we evaluate the safety&#xD;
      of such combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>olanzapine concentrations</measure>
    <time_frame>pharmacokinetic curve after a single dose of olanzapine alone or added to steady state fosamprenavir/ritonavir</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>fosamprenavir/ritonavir/olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 10 mg olanzapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosamprenavir/ritonavir</intervention_name>
    <description>16 days 700mg/100mg RTV BID</description>
    <arm_group_label>fosamprenavir/ritonavir/olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>15 mg olanzapine single dose</description>
    <arm_group_label>fosamprenavir/ritonavir/olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>10 mg olanzapine single dose</description>
    <arm_group_label>single dose olanzapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 and not older than 55 years at screening.&#xD;
&#xD;
          -  Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electro-cardiography, results of biochemistry, haematology and&#xD;
             urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry,&#xD;
             haematology and urinalysis testing should be within the laboratory's reference ranges.&#xD;
             If laboratory results are not within the reference ranges, the subject is included on&#xD;
             condition that the Investigator judges that the deviations are not clinically&#xD;
             relevant. This should be clearly recorded.&#xD;
&#xD;
          -  Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Positive hepatitis B or C test.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the&#xD;
             first dose) or breast-feeding female. Female subjects of childbearing potential&#xD;
             without adequate contraception, e.g. hysterectomy, bilateral tubal ligation,&#xD;
             (non-hormonal) intrauterine device, total abstinence, double barrier methods, or two&#xD;
             years post-menopausal. They must agree to take precautions in order to prevent a&#xD;
             pregnancy throughout the entire conduct of the trial.&#xD;
&#xD;
          -  Therapy with any drug (for two weeks preceding dosing), except for paracetamol.&#xD;
&#xD;
          -  Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, glaucoma, gastro-intestinal disorders, renal and hepatic disorders,&#xD;
             hormonal disorders (especially diabetes mellitus), coagulation disorders.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the trial and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug trial within 60 days prior to the first dose.&#xD;
&#xD;
          -  Donation of blood within 60 days prior to the first dose.&#xD;
&#xD;
          -  Febrile illness within 3 days before the first dose.&#xD;
&#xD;
          -  History of narrow-angle glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCN, Radboud Universtity Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Jacobs BS, Colbers AP, Velthoven-Graafland K, Schouwenberg BJ, Burger DM. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. Int J Antimicrob Agents. 2014 Aug;44(2):173-7. doi: 10.1016/j.ijantimicag.2014.03.014. Epub 2014 May 23.</citation>
    <PMID>24929949</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <name_title>D.M. Burger, PharmD, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

